Cancer Risk Scores
Cross-source consensus on Cancer Risk Scores from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Benefits
Dosage & preparation
Evidence quality
Highlighted claims
- The scores are intended to complement, not replace, clinical judgement. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods
- Both LCA and LASSO scores were strongly associated with cancer risk when treated as continuous variables. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods
- Using a binary cut-off of at least 2 points identified patients with markedly elevated cancer odds for both scores. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods
- Both scores provided higher net benefit than investigating all patients from a 4% cancer risk threshold onward. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods
- The scores have not yet been validated in primary care settings or GI-led RDC services. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods
- At a 6% probability threshold, both scores reduced unnecessary interventions by about 30%. — Exploring a panel of serum biomarkers for cancer risk in patients with non-specific symptoms: a comparative analysis of feature selection methods